Mutational and transcriptional landscape of pediatric B-cell precursor lymphoblastic lymphoma.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
08 Apr 2024
Historique:
accepted: 23 03 2024
received: 12 01 2024
revised: 21 03 2024
medline: 8 4 2024
pubmed: 8 4 2024
entrez: 8 4 2024
Statut: aheadofprint

Résumé

Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in bone marrow/blood (BCP acute lymphoblastic leukemia, BCP-ALL) or less common in extramedullary tissue (BCP lymphoblastic lymphoma, BCP-LBL). Although both presentations are similar in morphology and immunophenotype, molecular studies are virtually restricted to BCP-ALL so far. The lack of molecular studies on BCP-LBL is due to its rarity and the restriction to small, mostly formalin-fixed paraffin embedded (FFPE) tissues. Here we present the first comprehensive mutational and transcriptional analysis of what we consider the largest BCP-LBL cohort described to date (n=97). Whole exome sequencing indicates a mutational spectrum of BCP-LBL strikingly similar to that found in BCP-ALL. However, epigenetic modifiers were more frequently mutated in BCP-LBL, whereas BCP-ALL was more frequently affected by mutation in genes involved in B-cell development. Integrating copy number alterations, somatic mutations and gene expression by RNA-sequencing revealed that virtually all molecular subtypes originally defined in BCP-ALL are present in BCP-LBL too, with only 7% of lymphomas that were not assigned to a subtype. Similar to BCP-ALL, the most frequent subtypes of BCP-LBL were high hyperdiploidy and ETV6::RUNX1. Tyrosine kinase/cytokine-receptor rearrangements were detected in 7% of BCP-LBL. These results indicate that genetic subtypes can be identified in BCP-LBL using next-generation sequencing, even on FFPE tissue, and may be relevant to guide treatment.

Identifiants

pubmed: 38588489
pii: 515663
doi: 10.1182/blood.2024023938
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Society of Hematology.

Auteurs

Emma Kroeze (E)

Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands.

Ingram Iaccarino (I)

Kiel University, Kiel, Germany.

Michelle M Kleisman (MM)

Princess Maxima Center for Paediatric Oncology, Utrecht, Netherlands.

Mayukh Mondal (M)

Kiel University, Kiel, Germany.

Thomas Beder (T)

University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Mouhamad Khouja (M)

UKSH Kiel, Hämatologie Labor der Spezialdiagnostik, Kiel, Germany.

Marc P Höppner (MP)

Kiel University, Kiel, Germany.

Marijn A Scheijde-Vermeulen (MA)

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Lennart A Kester (LA)

Prinses Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Monika Brüggemann (M)

Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

Claudia D Baldus (CD)

University Hospital Schleswig-Holstein, Kiel, Germany.

Gunnar Cario (G)

University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Reno S Bladergroen (RS)

Princess Maxima Center for Paediatric Oncology, Utrecht, Netherlands.

Nathalie Garnier (N)

Institute of Pediatric Hematology and Oncology, lyon, France.

Andishe Attarbaschi (A)

St. Anna Children's Hospital, Vienna, Austria.

Jaime Verdu-Amorós (J)

Hospital Clínico Universitario de Valencia, valencia, Spain.

Rosemary Sutton (R)

Childrens Cancer Institute, Randwick, Australia.

Elizabeth A Macintyre (EA)

Hopital Necker, Université de Paris, Paris, France.

Kenneth Scholten (K)

Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Laura Arias Padilla (L)

Pediatric Hematology and Oncology, University Hospital Muenster, Muenster, Germany.

Birgit Burkhardt (B)

Paediatric Haematology, Oncology and BMT, University Hospital Münster, Münster, Germany.

Auke Beishuizen (A)

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Monique L den Boer (ML)

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Roland P Kuiper (RP)

Princes Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Jan L C Loeffen (JLC)

Princess Maxima Centre for Pediatric Oncology, Utrecht, Netherlands.

Judith M Boer (JM)

Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.

Wolfram Klapper (W)

Department of Pathology, Kiel, Kiel, Germany.

Classifications MeSH